EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR T-cell therapy “Living drugs” in systemic lupus erythematosus

Leila Khalili, Alberto Nordmann-Gomes, Marta Mosca, Anca Askanase

Best Practice & Research Clinical Rheumatology · 2026-03 · 40 (1) · 102141

DOI: 10.1016/j.berh.2026.102141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Rheumatology, 2026-03. Verfasst von Leila Khalili und 3 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Irving Medical Center, Department of Medicine, Division of Rheumatology, New York, NY, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative therapeutic option for patients with severe, refractory autoimmune conditions. Since 2022, several authors have published their experience using CAR T-cell therapy for patients with systemic lupus erythematosus (SLE). METHODS This narrative review summarizes the biological rationale, diverse modalities, targets and platforms, the emerging clinical efficacy and safety data, as well as the barriers and innovations regarding the use of CAR T-cell therapy in SLE. RESULTS Among the 16 studies reviewed, 13 evaluated products targeting CD19 and the remaining three bispecific products targeting CD19 and B-cell maturation antigen (BCMA). Twelve studies assessed autologous therapies and four allogeneic products. Therapies evaluating CAR natural killer cells (CAR-NK), gamma delta T-cells (γδ T-cells), other transduction methods, and even in vivo CARs are currently being evaluated. Early data has demonstrated significant clinical efficacy, including rapid disease activity reductions, drug-free remission in over 80%, achievement of low-level disease activity in almost 90%, and remission in 70% of the patients where these outcomes were assessed. Cytokine release syndrome occurred in 56% of the patients evaluated, almost exclusively being grade 1 or 2 events, and neurotoxicity was rare. CONCLUSIONS CAR T-cell therapy has demonstrated encouraging clinical efficacy and reassuring safety outcomes so far. However, longer prospective studies are needed to assess durability of response, long term safety, factors associated with poor response, and the appropriate selection and timing of patients for therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansT-LymphocytesAntigens, CD19B-Cell Maturation Antigen

Stichwörter der Autor:innen

CAR T-cell therapyCellular therapyChimeric antigen receptorSystemic lupus erythematosus

Substanzen

Receptors, Chimeric AntigenAntigens, CD19B-Cell Maturation Antigen

Autor:innen und Institutionen

  • Columbia University Irving Medical Center, Department of Medicine, Division of Rheumatology, New York, NY, USA.
  • University of Pisa, Pisa, Italy.
  • Columbia University Irving Medical Center, Department of Medicine, Division of Rheumatology, New York, NY, USA. Electronic address: ada20@cumc.columbia.edu.

Zitieren

APA

Khalili, L., Nordmann-Gomes, A., Mosca, M., & Askanase, A. (2026). CAR T-cell therapy “Living drugs” in systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology, 40(1), 102141. https://doi.org/10.1016/j.berh.2026.102141

Vancouver

Khalili L, Nordmann-Gomes A, Mosca M, Askanase A. CAR T-cell therapy “Living drugs” in systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology. 2026;40(1):102141. doi:10.1016/j.berh.2026.102141

BibTeX
@article{Khalili2026,
  author = {Khalili, Leila and Nordmann-Gomes, Alberto and Mosca, Marta and Askanase, Anca},
  title = {CAR T-cell therapy “Living drugs” in systemic lupus erythematosus},
  journal = {Best Practice & Research Clinical Rheumatology},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {102141},
  doi = {10.1016/j.berh.2026.102141}
}
Kostenlos starten →